Despite Amicus Therapeutics' recent share price uptick and steady revenue growth, the market's high expectations are reflected in the share price fall over the past three years. The company's 3.2% total shareholder return over the last twelve months falls short of the market return.
Investors might overlook Amicus Therapeutics' below industry-level growth forecast, risking future disappointment if the P/S ratio falls in line with the growth outlook. Moderate P/S ratio poses a risk as weaker revenue outlook might lead to share price drop.
$アミカス セラピューティクス(FOLD.US)$Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis. GALACTIC-1 trial did not meet its primary endpoint. Galecto to discontinue the development of GB0139.
$アミカス セラピューティクス(FOLD.US)$Following the sale, the chief executive officer now owns 689,618 shares of the company's stock, valued at approximately $7,261,677.54. he just needed the money for somthing if it was bad news we dont know yet then he would have sold way more
アミカス セラピューティクスに関するコメント
GALACTIC-1 trial did not meet its primary endpoint.
Galecto to discontinue the development of GB0139.
$アミカス セラピューティクス(FOLD.US)$ applies for FDA approval and Is merging a new company.
まだコメントはありません